The public shareholders of Zentiva Slovakia have sold approximately a 3% stake in the company to Sanofi, in a share buyback transaction. Financial details have not been disclosed.
Sanofi is a global and diversified healthcare leader which researches, develops and distributes therapeutic solutions focused on patients’ needs. The company has core strengths in healthcare, with six growth platforms: emerging markets, vaccines, consumer healthcare, diabetes treatments, innovative products and animal health.
Zentiva Slovakia is a producer of pharmaceutical products. Its product range consists of approximately 270 references in 500 pharmaceutical presentations, of which 180 are bound by prescription and 100 are OTC preparations or food supplements. The company focuses on the treatment of cardiovascular disorders, inflammatory conditions, pain, infections and diseases of the central nervous system and the gastrointestinal and urinary tracts. It also offers over-the-counter medicines and dietary supplements. It offers a range of therapeutic areas. In addition to generic drugs, Zentiva Slovakia also produces cosmetics and pharmaceutical substances.
Oaklins' team in Slovakia acted as financial advisor to the buyer in this transaction.
© 2019 Oaklins. All rights reserved. Oaklins is the collective trade name of independent member firms affiliated with Oaklins International Inc. For details of the nature of affiliation, please refer to www.oaklins.com/legal.